Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 22 clinical trials
Study of Exemestane After Anastrozole or Letrozole Treatment of Postmenopausal Women With Hormone Responsive Breast Cancer

node positive breast cancer randomized between anastrozole/letrozole 5 years and anastrozole/letrozole 2-3 years switching to exemestane 3-2 years.

lumpectomy
invasive carcinoma
endocrine therapy
anastrozole
ductal carcinoma in situ
  • 0 views
  • 07 Nov, 2020
  • 1 location
Pembrolizumab and Exemestane/ Leuprolide in Premenopausal HR+/ HER2- Locally Advanced or Metastatic Breast Cancer

This is an open-label, single-arm, multicenter, pilot study of pembrolizumab, exemestane, and leuprolide for subjects being resistant for front-line hormonal therapy for inoperable locally

  • 2 views
  • 13 May, 2021
  • 1 location
Exemestane Letrozole or Anastrozole in Treating Postmenopausal Women With Clinical Stage II and III Estrogen Receptor Positive Breast Cancer

are exemestane, anastrozole, letrozole. The purpose of this study is to find out whether it is better to receive exemestane, anastrozole, or letrozole to improve the chance that the

letrozole
hormone therapy
exemestane
anastrozole
estrogen receptor
  • 6 views
  • 07 Nov, 2020
  • 1 location
Ph3 Study of Exemestane With or Without Entinostat in Chinese Patients With Hormone Receptor-Positive Locally Advanced or Metastatic Breast Cancer

The purpose of this randomized phase III trial is to evaluate the clinical benefit of combining entinostat with exemestane in Chinese patients with HR-positive, HER2-negative, locally advanced

liver metastasis
denosumab
goserelin
erbb2
immunohistochemistry
  • 8 views
  • 23 Jan, 2021
  • 1 location
A Study of LXI-15029 in Patients With Advanced Malignant Solid Tumors

epidermal growth factor receptor 2 (-) in combined with Exemestane period , including confirmation of the maximum tolerated dose(MTD) of the combined therapy with Exemestane.

epidermal growth factor receptor
erbb2
lxi-15029
tumor cells
locally advanced breast cancer
  • 18 views
  • 26 Jan, 2021
  • 1 location
The XENERA 1 Study Tests Xentuzumab in Combination With Everolimus and Exemestane in Women With Hormone Receptor Positive and HER2-negative Breast Cancer That Has Spread

The main objective of the trial is to assess the efficacy of xentuzumab in combination with everolimus and exemestane over everolimus and exemestane in patients with HR+/ HER2- advanced or

HER2
erbb2
endocrine therapy
everolimus
mammogram
  • 101 views
  • 12 May, 2021
  • 147 locations
Palbociclib for HR Positive / HER2-negative Isolated Locoregional Recurrence of Breast Cancer

modulator (such as tamoxifen) or an aromatase inhibitor (anastrozole, letrozole, exemestane) or fulvestrant (Faslodex). Premenopausal women and men may also receive a drug called an LHRH (luteinizing

HER2
invasive breast cancer
gnrh
endocrine therapy
anastrozole
  • 0 views
  • 10 May, 2021
  • 69 locations
Neoadjuvant Tucidinostat and Exemestane in Early Breast Cancer

This study is to evaluate the efficacy of tucidinostat combined with exemestane as neoadjuvant strategy in estrogen receptor-positive early breast cancer patients and explore the genetic model

estrogen
metastasis
invasive breast cancer
exemestane
estrogen receptor
  • 0 views
  • 24 Jan, 2021
  • 1 location
Exemestane in Hormone Receptor Positive High Grade Ovarian Cancer

In this Italian, multicenter, randomized, double-blind, placebo controlled, phase III study the efficacy of exemestane will be evaluated in addition to the standard front line treatment in

fallopian tube
cancer chemotherapy
tumor debulking
ovarian epithelial carcinoma
cancer of the ovary
  • 0 views
  • 25 Jan, 2021
  • 47 locations
PalbocIclib in PreMenopausal Women With ER Positive/HER-2 Negative MetAstatic Breast Cancer

. Patients will be randomized to receive either palbociclib + exemestane + OFS (Arm 1) or exemestane +OFS (Arm 2). Treatment will be continued until disease progression, unacceptable toxicities, or

  • 0 views
  • 23 Jan, 2021
  • 1 location